Sanofi's Easier to Use Hemophilia Drug Approved by US FDA
Sanofi 's treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US Food and Drug Administration, offering patients greater choice as the market for therapies grows.
The drug fitusiran, which will go by the brand name Qfitlia, is the first new treatment for both types of hemophilia — A and B. It can also be given to both patients who have antibodies that prevent replacement therapies from working, as well as those who don't have those antibodies.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
7 hours ago
- Time Business News
Eczema Therapeutics Sector Forecast to Reach $49.8 Billion by 2035, Fueled by Breakthrough Biologics
The global eczema therapeutics sector is undergoing a significant transformation, propelled by the emergence of advanced biologic therapies and growing awareness around skin health. According to projections from Prophecy Market Insights, the sector is expected to surge from USD 19.5 billion in 2025 to USD 49.8 billion by 2035, reflecting a robust compound annual growth rate (CAGR) of 9.9%. At the forefront of this shift is the increasing incidence of eczema—particularly atopic dermatitis—affecting millions globally. Characterized by chronic inflammation, severe itching, and skin barrier dysfunction, eczema is most common in infants and children but can persist into or begin in adulthood. In the United States alone, over 31 million individuals are living with eczema, as reported by the National Eczema Association. Growth Catalysts The rising prevalence of eczema is a primary factor behind the sector's momentum. Pediatric cases continue to climb, while adult diagnoses are also increasing as awareness and diagnostic capabilities improve. Urbanization and lifestyle factors are further contributing to the surge in cases across both developed and developing economies. Recent years have seen a paradigm shift in treatment approaches, thanks to the approval and adoption of innovative biologics such as Dupixent (dupilumab) by Sanofi and Regeneron and Abrocitinib , a selective JAK1 inhibitor by Pfizer. These advanced therapies have proven especially effective for patients with moderate to severe eczema who do not respond well to conventional treatments like corticosteroids or calcineurin inhibitors. Barriers to Access Despite the progress, the eczema therapeutics landscape faces notable challenges. Chief among them is the high cost of biologic therapies, which can limit access, particularly in low- and middle-income regions. Additionally, traditional treatments, though widely used, often carry risks such as skin thinning and hormonal imbalances, which can deter long-term adherence and physician recommendations. Opportunities in Innovation and Emerging Regions The future of eczema care lies in personalized and targeted treatments. Innovations in genomics, microbiome research, and drug delivery are paving the way for more precise therapies with fewer side effects. Emerging economies present significant untapped potential, with expanding healthcare infrastructure, government support, and rising consumer awareness around dermatological conditions. Sector Segmentation The eczema therapeutics industry is segmented based on multiple parameters: By Drug Class: Including corticosteroids, calcineurin inhibitors, PDE4 inhibitors, and biologics. Including corticosteroids, calcineurin inhibitors, PDE4 inhibitors, and biologics. By Treatment Type: Prescription medications, over-the-counter (OTC) products, alternative therapies, and home-based remedies. Prescription medications, over-the-counter (OTC) products, alternative therapies, and home-based remedies. By Eczema Type: Atopic, contact, seborrheic, dyshidrotic, and nummular eczema. Atopic, contact, seborrheic, dyshidrotic, and nummular eczema. By Route of Administration: Topical applications dominate, followed by oral and injectable options. Topical applications dominate, followed by oral and injectable options. By Distribution Channel: Hospital pharmacies, retail outlets, and increasingly, online platforms. Hospital pharmacies, retail outlets, and increasingly, online platforms. By Patient Demographic: Infants, children, and adults form the primary treatment groups. Regional Outlook North America remains the global leader, benefiting from advanced healthcare systems, strong R&D activity, and favorable insurance reimbursement models. Europe also demonstrates strong momentum, especially in nations such as Germany, France, and the UK. The Asia-Pacific region is emerging as the fastest-growing geography, driven by urbanization, increased healthcare spending, and rising patient volumes in countries like India and China. Latin America, the Middle East, and Africa, while currently smaller in scale, are poised for steady progress as investments in healthcare infrastructure and dermatological services increase. Competitive Landscape The eczema therapeutics field is highly dynamic, with a blend of pharmaceutical giants and emerging biotech innovators. Key players include: Sanofi S.A. Regeneron Pharmaceuticals Pfizer Inc. AbbVie Inc. Novartis AG LEO Pharma A/S GlaxoSmithKline plc AstraZeneca plc Galderma SA Incyte Corporation These companies are actively developing new therapies aimed at improving efficacy, reducing side effects, and expanding access across age groups and severity levels. Recent Developments Pfizer's oral JAK1 inhibitor Abrocitinib gained FDA approval in 2023, enhancing treatment options for patients requiring systemic therapy. gained FDA approval in 2023, enhancing treatment options for patients requiring systemic therapy. Sanofi and Regeneron are expanding Dupixent's indications through clinical trials targeting adolescents and younger children. indications through clinical trials targeting adolescents and younger children. A wave of startups is pursuing microbiome-focused and gene-based therapies that promise long-term, sustainable relief with minimal adverse reactions. Looking Ahead With innovation at the forefront, the eczema therapeutics sector is set for accelerated growth through 2035. Biologic advancements, expanding global awareness, and precision medicine are redefining treatment standards, offering renewed hope to millions living with this chronic skin disorder. TIME BUSINESS NEWS
Yahoo
14 hours ago
- Yahoo
VIRBAC: Paul Martingell is appointed chief executive officer of Virbac, effective September 1, 2025
Virbac announces the appointment of Paul Martingell as the chief executive officer of the Virbac group, effective September 1, 2025. Paul Martingell, 45, is recognized as a leader who has demonstrated his ability to engage and inspire international teams, manage complexity, and create value for all stakeholders. He holds an MBA with distinction in Mergers and Acquisitions and is a Chartered Accountant in the United Kingdom. He has over 25 years of extensive international experience, particularly in consumer health, consumer goods, and pharmaceuticals. His professional journey is marked by roles of increasing responsibility in Europe, Asia, and Latin America, first at Ernst & Young (EY), then at Reckitt Benckiser and Novartis Consumer Healthcare. For the past eleven years, he has been part of the executive committee that oversaw the merger of Boehringer Ingelheim's and Sanofi's Consumer Healthcare businesses. During this time, he led key regions and served as chief growth officer. For the last three years, he has held the position of senior vice president, region head for Europe and Latin America, a region generating close to 3 billion euros in revenue. He was also part of the leadership team that successfully completed the spin-off of Opella. Paul is a recognized leader for his ability to develop diverse and agile teams, lead growth and learning-oriented cultures. He has proven his ability in building collective visions and leading successful transformations in operational roles, to deliver superior performance. 'It is with great enthusiasm that I join the Virbac group and prepare to discover the exciting world of animal health. I look forward to working with Virbac's exceptional teams to continue building the future on the strong existing foundations, innovating, and creating a positive and lasting impact for animals, their owners, and veterinarians worldwide', Paul Martingell announced. Marie-Hélène Dick, chairwoman of the board of directors of Virbac, stated: ''with his impressive background, energy, benevolent leadership, human approach, proven experience in the consumer health sector, international culture, and ability to embrace new challenges, the board of directors believes that Paul Martingell will be able to guide the Virbac teams and contribute to the long-term development of the Group by bringing a new perspective.' On June 18, 2025, the Virbac board of directors, upon recommendation from the appointments and compensation committee, appointed Paul Martingell as chief executive officer, effective September 1, 2025. The board of directors extends its gratitude to Habib Ramdani for diligently and professionally serving as interim chief executive officer. About Virbac - Caring for animals together At Virbac, we are constantly exploring new ways to prevent, diagnose and treat the majority of animal pathologies. We develop care, hygiene and nutrition products to offer complete solutions to veterinarians, farmers and pet owners around the world. Our purpose: advancing the health of animals with those who care for them every day, so we can all live better together. Press contacts - Agence Libremullenlowe Julie Adam - - + 33 7 86 82 60 61 Melina Constantinidis - - +33 7 63 18 97 34 Attachment Virbac PR - new CEO
Yahoo
15 hours ago
- Yahoo
The Department of Health - Abu Dhabi and Sanofi Forge Strategic Alliance to Accelerate the Development of New Global Vaccines in Abu Dhabi
On the sidelines of a high-level US visit focused on healthcare innovation ABU DHABI, UAE, June 19, 2025 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, has signed a Memorandum of Understanding (MoU) with Sanofi, a research and development-driven, AI-powered healthcare biopharma company at the BIO International Convention 2025, in Boston, USA. The collaboration will leverage the Emirate's health-tech ecosystem and advanced research infrastructure to drive the development of new global vaccines and strengthen regional capabilities in vaccine manufacturing. In the presence of H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi and Laurie Gery. Global Head of Business Development, Vaccines at Sanofi, the agreement was signed during the BIO International Convention in Boston, USA, by Dr. Asma Al Mannaei, the Executive Director of the Health Life Sciences Sector at the DoH and Baptiste de Clarens, General Manager Greater Gulf, Vaccines at Sanofi. Dr. Asma Al Mannaei, the Executive Director of the Health Life Sciences Sector at the DoH, said: "DoH is partnering with Sanofi to expedite the development of new global vaccines. This initiative aims to shorten the timeline from early research to public availability by utilising advanced technologies, real-time data analysis, and conducting parallel clinical trial phases. By combining Sanofi's global scientific expertise with Abu Dhabi's state-of-the-art infrastructure, we set new benchmarks for resilience, innovation and international partnerships. Abu Dhabi offers a globally connected, purpose-driven environment for leading research and together we will drive a transformative change that will safeguard the health and well-being of our community while contributing to global health security." Both entities will work together to streamline regulatory processes, enhance manufacturing preparedness, and promote knowledge sharing between local and international experts. This partnership reflects Abu Dhabi's strategic goal to establish itself as a leading center for bio- and pharmaceutical innovation and underscores the emirate's commitment to advancing proactive, technology-driven healthcare solutions. Baptiste de Clarens, General Manager Greater Gulf, Vaccines, Sanofi, said: "The Memorandum of Understanding signed with the Department of Health – Abu Dhabi marks an encouraging step towards advancing global health security while reflecting our shared interest in addressing global health challenges through scientific partnership. This agreement allows us to examine how Sanofi's experience in vaccine development could complement Abu Dhabi's growing R&D ecosystem. Through this initial framework, we look forward to exploring opportunities for public-private collaboration in healthcare innovation." In addition, both the Department and Sanofi will advance clinical research and development planning, optimise resource allocation and establish the foundational terms for funding and access. These efforts are designed to enhance healthcare resilience and sustainability across Abu Dhabi's healthcare sector and beyond, expanding access to quality care for patients locally and globally. Led by DoH, a high-level delegation has embarked on a strategic mission to the United States from June 15 to 21, delegation will conduct over 20 strategic meetings and visits with public and private sector leaders across the U.S., aimed at knowledge exchange, investment opportunities and the signing of new agreements that accelerate the adoption of advanced health solutions. Representing Abu Dhabi's innovation ecosystem, the delegation includes key stakeholders such as the Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, PureHealth, and Etihad Cargo, New York University Abu Dhabi (NYUAD), Khalifa University, startAD and Mohamed bin Zayed University of Artificial Intelligence (MBZUAI). View original content: SOURCE The Department of Health - Abu Dhabi
